BRCA1 and pancreatic ductal adenocarcinoma: Application to the TCGA also indicates such increased sensitivity: in the TCGA pancreatic ductal adenocarcinoma cohort (PAAD), the original study using deconstructSigs could not detect signature 3 activity in samples with somatic subclonal mutations in genes BRCA1 and BRCA236, while CloneSig reports signature 3 exposure in some PAAD tumors.